Bleichroeder LP’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Bleichroeder LP’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-250,000	Closed	-$52.6K	–	83
2023 Q2	$52.6K	Hold	250,000	–	–	0.01%	63
2023 Q1	$40K	Hold	250,000	–	–	0.01%	59
2022 Q4	$139K	Hold	250,000	–	–	0.03%	49
2022 Q3	$298K	Hold	250,000	–	–	0.06%	49
2022 Q2	$158K	Hold	250,000	–	–	0.03%	59
2022 Q1	$285K	Hold	250,000	–	–	0.05%	74
2021 Q4	$563K	Hold	250,000	–	–	0.09%	62
2021 Q3	$855K	Hold	250,000	–	–	0.14%	54
2021 Q2	$748K	Hold	250,000	–	–	0.11%	56
2021 Q1	$808K	Hold	250,000	–	–	0.14%	50
2020 Q4	$530K	Hold	250,000	–	–	0.1%	45
2020 Q3	$292K	Hold	250,000	–	–	0.05%	53
2020 Q2	$226K	Sell	250,000 -250,000	-50%	-$238K	0.04%	55
2020 Q1	$419K	Hold	500,000	–	–	0.11%	45
2019 Q4	$480K	Buy	+500,000	New	+$549K	0.08%	36

Other funds holding INFI

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

Bleichroeder LP's INFI Position: Q3 2023 in Review

Bleichroeder LP sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q3 2023, closing a stake of 250,000 shares — an estimated $52.6K sold.

Bleichroeder LP first reported a position in INFI in Q4 2019 and held it in 15 quarters. The position peaked at $855K in Q3 2021. 3 funds tracked by Wall St. Rank hold INFI as of Q3 2023.

Bleichroeder LP reported no remaining Infinity Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
Bleichroeder LP sold 250,000 Infinity Pharmaceuticals, Inc. shares in Q3 2023, an estimated $52.6K.
Bleichroeder LP first reported a position in Infinity Pharmaceuticals, Inc. in Q4 2019 and held it in 15 quarters.
Bleichroeder LP's Infinity Pharmaceuticals, Inc. position peaked at $855K in Q3 2021.
3 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q3 2023.

Based on Bleichroeder LP's 13F filing for Q3 2023, filed 9 Nov 2023.